Mycophenolate mofetil-d4 is intended for use as an internal standard for the quantification of mycophenolate mofetil by GC- or LC-MS. Mycophenolate mofetil is a prodrug form of mycophenolic acid .1,2,3 In vivo, mycophenolate mofetil (12.5 mg/kg) increases duration of transplant motor activity in a rabbit model of retroperitoneal heterotopic heart transplantation.1 It eliminates formation of microbleeds and hemorrhages in the cerebrum of stroke-prone spontaneously hypertensive rats.2 Mycophenolate mofetil also lowers mean arterial pressure (MAP) and reduces urinary albumin excretion and glomerulosclerosis, markers of renal damage, in a mouse model of systemic lupus erythematosus (SLE).3
1.AygÜn, F., Efe, D., and Durgut, K.Comparison of MMF with prednisone in terms of rejection and duration of activity of transplant in rabbits that underwent retroperitoneal heterotopic heart transplantationCardiovasc. J. Afr.26(3)104-108(2015) 2.Dhande, I.S., Zhu, Y., Braun, M.C., et al.Mycophenolate mofetil prevents cerebrovascular injury in stroke-prone spontaneously hypertensive ratsPhysiol. Genomics49(3)132-140(2017) 3.Taylor, E.B., and Ryan, M.J.Immunosuppression with mycophenolate mofetil attenuates hypertension in an experimental model of autoimmune diseaseJ. Am. Heart Assoc.6(3)e005394(2017)